Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12851662 | 1.00 | CA2 (0.38) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL12990607 | 1.00 | CA2 (0.38) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL15691487 | 1.00 | CA2 (0.38) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL12191325 | 1.00 | CA2 (0.38) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL18685058 | 0.86 | CA2 (0.38) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL7151640 | 0.83 | CA2 (0.34) | CA2CA1CA9LMNACYP1A2 | |
| SCHEMBL15038520 | 0.82 | CA2 (0.43) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL25070349 | 0.81 | CA2 (0.38) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL20419296 | 0.81 | CA2 (0.36) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL1038767 | 0.79 | CA2 (0.33) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-8088746-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7741457-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7666854-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7569686-B1 | Compounds and methods for synthesis of bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547684-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | CA2 4371/4885CA1 4348/4885CA9 3205/4885 |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | CA2 4371/4885CA1 4348/4885CA9 3205/4885 |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | CA2 4186/4885CA1 4343/4885CA9 3327/4885 |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | CA2 4470/4885CA1 4557/4885CA9 3514/4885 |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | CA2 3031/4885CA1 4853/4885CA9 4428/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | CA2 3031/4885CA1 4853/4885CA9 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.